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Abstract 6 
The quantification of illicit drug and pharmaceutical residues in sewage has been shown to be a valuable tool 7 
that complements existing approaches in monitoring the patterns and trends of drug use. The present work 8 
delineates the development of a novel analytical tool and dynamic workflow for the analysis of a wide range of 9 
substances in sewage-based samples. The validated method can simultaneously quantify 51 target psychoactive 10 
substances and pharmaceuticals in sewage-based samples using an off-line automated solid phase extraction 11 
(SPE-DEX) method, using Oasis HLB disks, followed by ultra-high performance liquid chromatography 12 
coupled to quadrupole time-of-flight mass spectrometry (UHPLC-QTOF) in MSe. Quantification and matrix 13 
effect corrections were overcome with the use of 25 isotopic labeled internal standards (ILIS). Recoveries were 14 
generally greater than 60% and the limits of quantification were in the low nanogram-per-liter range (0.4-187 15 
ng L-1). The emergence of new psychoactive substances (NPS) on the drug scene poses a specific analytical 16 
challenge since their market is highly dynamic with new compounds continuously entering the market. Suspect 17 
screening using high-resolution mass spectrometry (HRMS) simultaneously allowed the unequivocal 18 
identification of NPS based on a mass accuracy criteria of 5 ppm (of the molecular ion and at least two 19 
fragments) and retention time (2.5 % tolerance) using the UNIFI screening platform. Applying MSe data 20 
against a suspect screening database of over 1,000 drugs and metabolites, this method becomes a broad and 21 
reliable tool to detect and confirm NPS occurrence. This was demonstrated through the HRMS analysis of three 22 
different sewage-based sample types; influent wastewater, passive sampler extracts and pooled urine samples 23 
resulting in the concurrent quantification of known psychoactive substances and the identification of NPS and 24 
pharmaceuticals.  25 
Keywords 26 
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1. Introduction 29 
The illicit use of psychoactive substances is a worldwide phenomenon with incalculable consequences on 30 
society. Estimates from 2012, indicate that between the 4 and 7 % of the world´s population has used an illicit 31 
substance at least once during the previous year [1]. Even though the overall European drug situation is 32 
generally stable, a graduated and complex situation is emerging [2]. Classic drugs, such as heroin, cocaine and 33 
cannabis remain dominant but the drug market is now peppered with a vast array of synthetic psychoactive 34 
substances. The EU Early Warning System for first time notified the discovery of 101 new psychoactive 35 
substances (NPS) in 2014 [3]. Illicit drug use and prevalence estimations are typically based on population 36 
surveys, clinical cases, seizures and mortality rates related to use. In addition to known problems with bias and 37 
a lack of representativeness, these approaches also require a long time to establish a general overview of the 38 
illicit drug situation and, generally, results are published several years post survey [4]. 39 
Pharmaceuticals arising from human, veterinary and aquaculture use, occur in the aquatic environment as one 40 
of the largest sources of contaminants of anthropogenic origin and have recently become a new environmental 41 
problem [5]. Many studies have been performed assessing the impact of hospitals and their contribution to the 42 
pharmaceutical loads found in wastewater [6-8], the efficiency of the removal of pharmaceuticals by 43 
wastewater treatment plants (WWTP) [9], the spatial and temporal differences of pharmaceuticals occurrence 44 
in wastewater [10] and recently to compare the results of the wastewater analysis with predicted concentrations 45 
based on prescription figures [11, 12]. In the context of sewage-based epidemiology (SBE) pharmaceutical 46 
residues also offer the potential to map certain types of disease and other health based stressors[13]. 47 
The measurement of illicit drugs and pharmaceuticals in wastewater has become an extended topic over the 48 
past decade and SBE has been established as a complementary approach for monitoring trends of illegal drug 49 
use [14-18]. Recently the approach has been evaluated with an international study comparing the drug 50 
consumption in 21 different countries by quantitatively analyzing illicit drugs and their metabolites in 47 51 
WWTP [19, 20]. SBE has been used to estimate drug use in communities (i.e. city, small town, school, prisons) 52 
as well as identify changes in drug consumption during special events [21, 22], temporal changes [17], and 53 
providing complementary data on the use of NPS [23-25]. Thus far, the analytical methods used for SBE have 54 
focused on the principal challenges related to the low concentrations of drug residues in wastewater combined 55 
with the complexity of the wastewater matrix. These procedures have been mainly developed for classic illicit 56 
drugs (cocaine, amphetamines, opioids and cannabis) and a broad range of pharmaceuticals, and based on 57 
solid-phase extraction (SPE) for sample pre-treatment and pre-concentration followed by instrumental analysis, 58 
typically liquid chromatography coupled to tandem mass spectrometry (QqQ)[5, 16]. 59 
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The hyphenation of liquid chromatography to high resolution mass spectrometry (HRMS), i.e. orbitrap and 60 
quadrupole time-of-flight (QTOF), has increased the potential of SBE to identify NPS and their residues in 61 
sewage based samples. HRMS offers some unique advantages for screening and identification, such as better 62 
specificity due to its increased resolving power and the possibility to perform retrospective analyses without the 63 
need of additional sample analyses [26]. 64 
Since the NPS market is in constant flux, new strategies are urgently required. New analytical methods based 65 
on QqQ for the target analysis of NPS are continuously being published[24, 25] but in general these techniques 66 
cannot keep up with the rapidly evolving NPS market making necessary the development of new approaches 67 
that combine target analysis with wide-scope suspect screening capable of confirming the presence/absence of 68 
a new compounds with quantification should reference standards be available[27]. This challenge can be 69 
overcome by using a suspect screening approach that has already been demonstrated as a suitable technique for 70 
the detection and confirmation of several organic compounds[27], including NPS[23, 28]. The simultaneous 71 
determination of a broad number of compounds in one injection, with a corresponding reduction of time and 72 
costs, without the need for reference standards make this approach one of the current trends in environmental 73 
analytical chemistry. 74 
The aim of the presented work was to establish a broad analytical tool for the analysis of different types of 75 
drugs in sewage-based samples, such as pooled urine, wastewater and passive sampler extracts and develop a 76 
dynamic workflow for the introduction of new substances of interest in the future due to the high potential of 77 
the HR-MS instruments for the identification of suspect compounds presented in the sample.. Firstly a targeted 78 
multi-residue method for the simultaneous identification and quantification of 51 drugs, pharmaceuticals and 79 
their main urinary metabolites by UHPLC/QTOF was validated as recommended by EU guidelines with minor 80 
modifications [29, 30]. With the target method established to track the quantitative occurrence of selected 81 
target analytes, the secondary goal of this work was to detect possible NPS and other compound of possible 82 
interest in sewage-based samples thought the use of a suspect screening approach. The present work also 83 
describes the potential of non-target analysis for identifying NPS and their subsequent inclusion into the 84 
suspect database or target method if standard reference is available through a dynamic approach. 85 
2. Materials and methods 86 
Detailed information relating to reagents and chemicals (illicit drugs, pharmaceuticals and metabolite reference 87 
substances), the sewage-based samples and extraction procedure can be found in the Supplementary 88 
Information (SI). 89 
 90 
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2.1 Sewage-base samples 91 
Influent samples were collected from two Norwegian WWTPs; VEAS WWTP in Oslo and Ladehammeren and 92 
Høvringen WWTP in Trondheim. The robustness of the method was also examined by analysing different 93 
sewage-based samples. The “Pharmaceuticals” version of the polar organic chemical integrative sampler 94 
(POCIS) was placed for two weeks in the sedimentation overflow channel at the Oslo WWTP and the pooled 95 
urine samples were collected from three different Norwegian music festivals. Figure 1 shows an overview of 96 
the samples used in this study (detailed information provided in SI). 97 
2.2 Extraction procedure 98 
Defrosted sewage samples (100 mL) were spiked with a mix of 25 isotope labeled internal standards (ILIS) to 99 
give a concentration of 400 ng L-1. The pH was controlled but generally was the desired (~7). Subsequently, 100 
extraction was performed using a SPE-DEX fully automatable extraction system (Horizon Technology, Salem, 101 
NH, USA) using HLB (Hydrophilic-Lipophilic Balance) extraction disks (47 mm, I.D.; Horizon Technology, 102 
City, Country) (more information in SI and Table S-1). 103 
The selection of the Oasis HLB extraction sorbent was based on previous experience. Oasis HLB and MCX 104 
generally yield the highest recoveries for most of the drugs and pharmaceuticals [5, 18]. Compared with Oasis 105 
MCX, HLB provides a lower selectivity for some basic compounds, such as amphetamine-like compounds and 106 
a considerable increase of the matrix components retained in the sorbent leading to a higher sensitivity. Despite 107 
this, HLB, with a mixed-mode cation exchange sorbent, offers the possibility to extract a wide range of 108 
compounds with different psychochemical characteristics suiting the goal of the method, enabling the 109 
simultaneous analysis of the widest range of drugs and pharmaceuticals in one single extraction. 110 
To determine the method recovery influent wastewater from VEAS WWTP in Oslo was spiked in quintuplicate 111 
with a standard mixture containing all of the target analytes at two different concentrations together with a 112 
mixture of the 25 ILIS. The two concentrations were selected according to those generally found in wastewater 113 
influent. 114 
2.3 Ultra-high pressure liquid chromatography  115 
The chromatography column, stationary phase and mobile phases were selected in accordance with a pre-116 
established screening method[31]. Figure 2 shows the 2D mass chromatogram of the low energy channel (6eV 117 
ESI+) for the optimal separation of all target compounds and NPS at a concentration of 250 ng mL-1. A Waters 118 
Acquity UPLC system (Milford, MA, USA) was used for this work. Chromatographic separation was carried 119 
out using an Acquity UPLC HSS C18 column (2.1 x 150 mm, particle size 1.8 µm) (Waters, Milford, MA, 120 
USA). Gradient elution was performed at a constant flow of 0.4 ml min-1 using 5 mM ammonium formate, pH 121 
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3.0 (solvent A) and acetonitrile with 0.1 % formic acid (solvent B). The gradient elution starts with 87% A and 122 
then increasing B to 95% in 15 minutes: Solvent A, held for 0.5 min; 0.5-10 linear rate to 50% B, 10-10.75 123 
linear rate to 95% B, held for 0.5 min; reconditioning with a linear rate to 87% A, 12.50-15 min. The analytical 124 
column and the guard column were kept at 50 ºC and the sampler manager at 5 ºC. The weak and strong wash 125 
used to remove the contaminants from the needle and the injection port were 10% ACN in water (600 μL) and 126 
95% ACN in water (200 μL) respectively. 127 
2.4 Quadrupole Time-of-flight Mass Spectrometry 128 
A Xevo G2-S Q-TOF mass spectrometer (Waters, Milford, MA USA) was used in positive ESI mode for 129 
acquisition using MSe, that allows both precursor and product ion data to be simultaneously acquired during a 130 
single run. The MS method consists of 3 functions, the first (low energy, LE) applies collision energy of 6 eV, 131 
the second function (high energy, HE) acquires through a collision energy ramp of 15-50 eV and the third 132 
function acquires the lock mass data for online mass calibration. The MS range is 70-700 with a scan time of 133 
0.1 second in continuum mode, preserving the peak shape of the exact-mass precursor and product ions. The 134 
source conditions whose maximum intensities were achieved were the following: capillary voltage 3 kV, 135 
sample cone, 20 V, source offset 80 V, source temperature 120 ºC, desolvation temperature 500 ºC, cone gas 136 
flow rate 50 L h-1, desolvation gas (N2) flow rate 1000 L h
-1.  137 
The mass spectrometer was calibrated using a solution of sodium formate over a mass range of 50-1000 Da. 138 
Analyses were performed using an external reference (Lock-Spray™). During the data acquisition the mass 139 
was corrected using an external reference (Lock-Spray™) consisting of 0.2 µg mL-1 solution of leucine-140 
enkephalin infused continuously at 10 µL min-1 via a lockspray interface. The lock mass data were acquired 141 
every 20 seconds for 0.1 seconds and for the rest of the time the baffle in the ion source blocked the entry of 142 
the lock spry. This generated a reference ion in positive mode at m/z 556.2771 that was used for real-time mass 143 
corrections in order to maintain the mass accuracy and reproducibility. 144 
2.5 Data processing 145 
The workflow and identification confidence used in this work were based upon those described by Krauss et al. 146 
[32] and Schymanski et al. [33](Figure 3).  147 
The MSe data processing using the UNIFI screening platform (Waters Corporation, Milford MA, USA) was 148 
performed in two steps.  Firstly, all the continuum data was peak detected using a 3D peak algorithm based on 149 
the calculation of the peak volumes by the detection of all the ion crests in a given mountain range.  This 150 
provides a complete list of retention-time / m/z-pairs which are then used for screening.  The second step which 151 
follows peak detection is the screening protocol where Unifi matches the observed m/z retention-time pairs 152 
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against the scientific database using defined settings such as the retention time accuracy (2.5 %), mass accuracy 153 
of parent ion and fragment ions (5 ppm) and theoretical isotope patterns for the protonated molecule at LE and 154 
at least two accurate fragment ions at HE [30]. The database is built from a pre-established screening method 155 
[31] which uses the same chromatographic and detector parameters as in this study. 156 
For target screening the procedure is unchanged, except the screening is focused only on the 51 target 157 
compounds (as opposed to the entire 1000 + library) and reference standards are run with the analysis to prove 158 
quantitative information/results (Table 1). Protonated precursor ion data at LE was extracted and used for 159 
quantification.  For this work, selection of the 51 target analytes was based on their reported use in Norway and 160 
their previously reported occurrence in wastewater [17, 19, 24].  161 
For suspect screening, the retention-time/ m/z-pairs are compared against a broad list of approximately 1000 162 
compounds (note that this database is under constant renewal and expansion so the exact number of compounds 163 
varies over time). UNIFI also automatically assesses the candidate values with the fragments, mass defect, 164 
isotope pattern and adducts (M+H, M+Na, M+NH4). The suspect screening database (including mass spectra, 165 
assigned fragments and retention time) was applied under the same acquisition parameters as above and tested 166 
in this work on pooled urine samples in an attempt to identify NPS or possible compounds of interest to include 167 
in the future in the target method through a reiterative development workflow. 168 
While the current study used a screening database developed around a commercially product, and manually 169 
augmented with 16 NPS, suspect screening may also be performed using other public databases (e.g. 170 
MassBank, Chemspider) or in-silico fragmentation tools (MetFrag) which are available for many 171 
environmental contaminants. Suspect screening lists may also be produced with computational prediction 172 
systems that can provide a list of potential excreted biomarkers and biotransformation products in wastewater 173 
[34]. 174 
Directly infusing the standards and subsequently analyzing the spectra usually calculate fragmentation 175 
pathways. This study attempts to complement the suspect-screening database by importing suspect candidates 176 
relying on accurate spectral information and different non-target tools. Where analytical data on fragmentation 177 
is lacking the UNIFI fragment match tool applies a series of novel algorithms based on systematic bond 178 
disconnections of the precursor structure to predict fragmentation pathways that can then be compared with 179 
measured spectra in order to help to increase the amount and the reliability of the information essential for the 180 
subsequent identification and confirmation of the compound of interest. This approach has been tested in this 181 
study with two NPS. The common fragment approach is another interesting option for the detection of NPS. 182 
Synthetic cannabinoids generally appear on the market with minor structural modifications which means that 183 
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during fragmentation they lose the same specific functional groups and that structural information can be used 184 
as a filter to detect those components. This tool has been tested with 14 different synthetic cannabinoids. 185 
2.6 Quantification and method validation 186 
The performance of the method was evaluated following EU guidelines with minor modifications[29, 30]. The 187 
instrumental linearity of the method was studied by analyzing standard solution in triplicate at 9 different 188 
concentrations that were between 0.25 ng mL-1 and 500 ng mL-1 (it would be equivalent to 1-2000 ng L-1 in 189 
sewage after applying the pre-concentration factor). Satisfactory linearity was assumed when the correlation 190 
factor (R2) was > 0.99, based on analyte/internal standard peak area ratio applied in different concentration 191 
ranges for each compound. The most relevant aspects about the instrumental parameters are summarized in 192 
Table S-2. 193 
The theoretical limit of quantification (LOQTHE) for real samples was calculated based on the ratio between the 194 
instrumental limit of quantification, estimated as a signal-to-noise (S/N) ratio of 10 for the standard in the 195 
calibration curve at the lowest level, and the matrix suppression (MS) for each deuterated internal standard 196 
multiplied by the concentration factor (CF). 197 
 198 
The matrix effect defined as Matuszewski et al.[35] was calculated as the ratio between the accurate mass 199 
signal of the 25 deuterated standard spiked in different sewage samples after extraction and the accurate mass 200 
signal of the same deuterated standard in the calibration curve. The influence of the sewage matrix 201 
concentration on the analysis is a crucial factor but simply controlled with a pre-concentration factor study[36]. 202 
For analytes where deuterated standards were unavailable, either the deuterated analyte with similar structure, 203 
polarity or the closest retention time was selected for correction.  204 
Precision was expressed as the repeatability of the method in terms of relative standard deviation and trueness 205 
was tested by means of the absolute recovery due to the lack of quality control standards. The relative 206 
recoveries and standard deviations of the whole procedure were calculated by analyzing sewage water samples 207 
spiked at a low and high concentration with the analytes (100 and 600 ng L-1) according to the levels generally 208 
found in wastewater and with 600 ng L-1 of the deuterated internal standard solution mix. All recovery 209 
experiments were performed in six replicates (n=6). Concentrations of target compounds found in wastewater 210 
“blank” samples were subtracted from the spiked samples due to the absence of an appropriate wastewater 211 
blank. Instrumental accuracy and precision was assessed by analyzing spiked Mili-Q water (n=5) at two 212 
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different concentrations for each compound, low level (between points 2-3 on the calibration curve) and high 213 
level (between points 8-9 on the calibration curve). 214 
The stability of the target analytes in wastewater was evaluated in triplicate (n=3) via the analysis of 500 mL of 215 
spiked (1000 ng mL-1) wastewater immediately following spiking (t=0 hours) and again at t=5, 8 and 120 hours 216 
post spiking. The wastewater sample (pH 7.5) was stored in an amber glass bottle at 10 ºC throughout the study 217 
in order to best replicate the average wastewater influent temperature.  218 
 219 
3. RESULTS AND DISCUSSION 220 
3.1 Sample extraction optimization 221 
Selected parameters were investigated in order to optimize the method. Silanisation of the glassware, by 222 
deactivating the ion-exchange groups with dichlorodimethylsilane, resulted in increased recoveries for some of 223 
the more polar drugs, such as amphetamine-like compounds (Figure S-1). Elevated evaporation temperature 224 
was also found to result in analyte losses, therefore special attention was paid to the drying of extracts .Figure 225 
S-2 shows poor recoveries for some of the phenethylamines following nitrogen evaporation at 50°C. All 226 
samples were subsequently evaporated to around 100 µL under a gentle nitrogen stream at 35 ºC. 227 
3.2 Method performance  228 
The relative recoveries and standard deviations from the relative responses analyte/ILIS are shown in the Table 229 
S-3. For the target analytes with corresponding ILIS the recoveries are typically >80% with some exceptions 230 
such as MDMA, norketamine and atomoxetine with slightly lower recoveries of around 70%. The remaining 231 
target analytes were corrected using the ILIS with the closest structure, polarity or eluting time, achieving 232 
relative recoveries ranging from 60 to 118%. However certain analytes such as clonazepam (56%), 233 
dehydronorketamine (53%), methoxetamine (40%) and methylphenidate (50%) showed lower recoveries. 234 
Relative recoveries at 100 ng L-1 are in general slightly lower due their proximity to the LOQTHE, however in 235 
general the recoveries do not substantially differ between the low and high concentration. The overall method 236 
precision was calculated as the relative standard deviation (RSD) due to the lack of reference materials for the 237 
wastewater samples, and showed satisfactory results <20% RSD for all compounds. 238 
Paracetamol and hydroxycotinine were detected at high concentrations in the blank (low ppb) making 239 
subtraction and the recovery calculation not possible for paracetamol, and less precise for hydroxycotinine 240 
(highest RSD). Carbamazepine also exhibits ionization issues in terms of signal enhancement with recoveries 241 
slightly higher than 100% while other compounds with high signal suppression were gabapentin, p-242 
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hydroxymethamphetamine, MDA, diclofenac, THC-OH and THC-COOH, which were finally excluded from 243 
further validation in this study, but this does not however preclude the potential for lower matrix effects and 244 
better analytical outcomes in wastewater from other locations or other sample types that present a cleaner 245 
matrix.  246 
The overall method recoveries were satisfactory and similar to those screening methods previously reported for 247 
pharmaceuticals in wastewater samples [5]. Different target procedures, such as QqQ, with optimized and 248 
specific conditions for each analyte, generally present greater sensitivity. This is a downside of all multi-249 
residue methods where the optimized conditions are compromised in order to accommodate several analytes, 250 
especially in complex and variable matrix such as wastewater. Nevertheless the good sensitivity levels and 251 
dynamic range presented in the new HR-MS instruments together with the instrumental performance in terms 252 
of repeatability and sensitivity helps to counteract low recoveries. 253 
3.3 Quantification and method validation 254 
Table S-2 provides an overview of the performance of the developed target method. The instrumental linearity 255 
for nine concentration levels is in the range of 0.25 to 400 ng mL-1, equivalent to 1-2,000 ng L-1 in wastewater 256 
after applying the pre-concentration factor. These are within the levels reported in literature[16] showing good 257 
results for all of the initial 51 selected compounds presenting correlation coefficients greater than 0.99. 258 
Different ranges were applied for every compound according to sensitivity. Instrumental LOQ was calculated 259 
as the signal-to-noise (S/N) ratio of 10 for the standard in the calibration curve at the lowest concentration. 260 
Instrumental accuracy and precision, both for intra- and inter-day, was assessed at two different concentration 261 
levels for each compound showing an satisfactory accuracy levels between 87.8-113.1 % range and precision 262 
<12.8 % (RSD). 263 
The theoretical limits of quantification (LOQTHE, Table S-3), calculated based on the ratio between the 264 
instrumental limit of quantification and matrix suppression multiplied by the concentration factor for each 265 
deuterated internal standard, varied between 0.4 and 187 ng L-1. This is just a valuable estimation about the 266 
method performance and due to the complexity of the matrix common sense has to be used prior the analysis of 267 
a new batch of samples. 268 
The instrumental performance was also evaluated in terms of the intra-day (repeatability) and inter-day 269 
(reproducibility) precision studies from five spiked Mili-Q water samples at two different concentration levels 270 
in five repeated injections and three consecutive days. The results in terms of RSD show values below 10% in 271 
both intra and inter-day studies for all the compounds except for THC-COOH at the low concentration level for 272 
the intra-day (10.2%) and amphetamine and flunitrazepam at the low concentration level for the inter-day (11.8 273 
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and 12.8 respectively). The good instrumental performance together with the high selectivity reached and low 274 
mass error for all the target compounds (mass error range between -0.51 and 0.39 mDa, (Table S-2) ensure the 275 
reliability of the instrument performance, an essential aspect in HRMS. 276 
3.4 Liquid Chromatography-Mass Spectrometry  277 
Suppression or enhancement of the target ion signal in LC-MS is a critical issue in wastewater analysis due to 278 
the complex nature of the sample and the co-elution of the analytes with matrix constituents. The negative 279 
consequences of this problem are best avoided with the use of appropriate ILIS, together with extensive sample 280 
pre-treatment (clean-up), chromatographic separation and sample dilution. The effects of the sample matrix 281 
was evaluated by comparing the matrix effect/pre-concentration factor ratio for all the 25 deuterated internal 282 
standards. Deuterated internal standards are not present in sewage water samples but are affected by the same 283 
potential losses during the analytical process as the analyte of interest. The influence of the SPE loading 284 
volume on matrix suppression was optimized by spiking 100 ng of the deuterated internal standard mix 285 
solution into the extracts of 3 different wastewater extracts at 4 different volumes (100, 200, 300, and 400 mL). 286 
The accurate mass signal was compared with the accurate mass signal of the deuterated internal standards in 287 
solvent. A loading volume of 100 mL was found to give the most satisfactory compromise for the analysis with 288 
a pre-concentration factor of 250 (LC vial volume 400 µL, injection volume 5 µL) (Figure S-3). 289 
Van Nuijs et al.[37]considered not including matrix effect studies in method validation, claiming that matrix 290 
effects can be highly variable between samples. We agree on the fact that each individual sample has a 291 
different composition, but we strongly recommend the matrix characterization of different batches of 292 
wastewater samples when they come from different locations or affected by different conditions since an 293 
appropriate sample dilution can improve substantially the general performance of the method. Generally 294 
analytical methods rely on the validated LOQ but wastewater analysis required a more intense day-to-day 295 
control. 296 
3.5 Stability in wastewater 297 
The stability of the analytes in wastewater was investigated to ensure the use of appropriate sample-storage and 298 
handling procedures. The study was configured to estimate the degradation of our target compounds during the 299 
in-pipe transit time for a single wastewater sample. 300 
Table S-4 shows the results for the stability test for the target analyte signal in non-filtered wastewater at pH 301 
7.5 and 10°C expressed as the difference between initial and final concentrations at different time points (t= 0, 302 
5, 8 and 120 hours). Time points were set according the mean residence time in the sewer system from Oslo to 303 
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the VEAS WWTP, 5 hours, the total treatment time in the plant, 3 hours, and finally a long exposure during 304 
120 hours to provide an estimation of the biodegradation after 5 days.  305 
Over the first 5 hours EDDP is the only analyte with major change in peak area (45% higher). Between 5 and 8 306 
hours significant changes were also observed for hydroxycotinine, benzoylecgonine, methylphenidate the 307 
concentration changed substantially (>±30 %). The results following 120 hours show degradation for the many 308 
of the target analytes, such as morphine (83%), p-hydroxymethamphetamine (70%), paracetamol (-88%), MDA 309 
(-96%), methylphenidate (-88%), cocaine (-75%), EDDP (77%), nitrazepam (-79%) and phenazepam (-70%). 310 
These data provide an indication of the transformation that may occur during in-sewer transport. The results are 311 
in accordance with previous reports [38].  312 
3.6 Application to sewage water samples 313 
  3.6.1 Target Screening.  314 
The main objective of this work was to demonstrate the broad applicability of a multi-residue method in MSe 315 
by UHPLC-QTOF for both screening and quantification purposes. The validated method was applied to the 316 
analysis of 15 wastewater samples collected from two WWTPs in Oslo and Trondheim in 2014 to assess the 317 
applicability of the method. Table 2 shows the population normalized loads for the target drugs in wastewater, 318 
estimated from the daily concentration of each detected target compound in the wastewater sample, daily flow 319 
discharged into the WWTP and by the population size (mg day-1 1000 inhabitants-1). Results from Oslo show 320 
the daily average loads calculated from the analysis in triplicate of a daily composite sample taken every 321 
Friday, Saturday and Sunday during three consecutive weekends. 322 
In general, pharmaceuticals were detected in higher concentration for both cities. Atenolol, paracetamol, 323 
metoprolol, propranolol, citalopram, carbamazepine, oxazepam were detected at elevated concentrations in all 324 
of the samples from Oslo and Trondheim. Methylphenidate and alprazolam were only present in samples from 325 
Trondheim, suggesting different levels of consumption within the same country.  326 
The heroin metabolites, 6-MAM and morphine, were detected in samples from both locations but it is 327 
important to remember that while 6-MAM is specific to heroin, the presence of morphine in wastewater also 328 
can result from the clinical use of legal pharmaceuticals containing morphine or codeine. Methadone and its 329 
metabolite, EDDP, are usually present in wastewater samples and in this study the loads obtained in Oslo are 330 
approximately ten times higher than those from Trondheim. Biomarkers of other commonly used drugs, such as 331 
cocaine, benzoylecgonine, amphetamine and methamphetamine were detected in samples from both cities at 332 
different concentrations. While the loads of cocaine/benzoylecgonine are approximately ten timers higher in 333 
Oslo than in Trondheim, the results for amphetamine and methamphetamine are slightly higher in Trondheim 334 
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suggesting different use patterns. This is in agreement with the general geographical distribution of the drugs in 335 
Norway published in the Annual report to the European Monitoring Centre for Drugs and Drug Addition[39] 336 
where cocaine seems to be a big city phenomenon with special relevance in Oslo and at the same time within 337 
the European context Norway has been shown to have one of the biggest market for 338 
amphetamine/methamphetamine[39]. 339 
Cocaethylene, the main urinary biomarker of cocaine co-consumption with alcohol, and MDMA were 340 
identified and quantified only in Oslo. Methylone, ketamine and methoxetamine were found in at least one of 341 
the composite samples from Oslo suggesting a sporadic weekend use. 342 
This method is also been successfully used for the analysis of other sewage-based samples, such as pooled 343 
urine samples and passive sampler extracts. Sample preparation was adapted for each case (SI). It is worth 344 
mentioning the importance of the dilution factor for both POCIS and pooled urine samples since the 345 
concentration level for the target biomarkers are extraordinary high compared with those typically found in 346 
wastewater, being a very suitable samples for suspect screenings. 347 
Table S-5 and S-6 show the results of the target analysis performed on 10 POCIS extracts from the winter of 348 
2013 and three pooled urine samples collected from three different music festivals in summer of 2014.The 349 
results for the passive sampling devices must be corrected with an exposure factor, however this is outside of 350 
the scope of this paper and therefore the results are presented as amount of analyte (ng) per POCIS. The target 351 
method was also used for the analysis of the pooled urine samples collected from music festivals. 352 
In general the compounds identified in the POCIS do not differ with the compounds obtained and reported in 353 
this study for the wastewater samples, however in the pooled urine samples the differences are greater, 354 
especially for the amphetamine-like compounds exposed to a lower dilution factor compared with the other 355 
sewage-based samples. The low dilution factor makes pooled urine samples a very suitable sample for suspect 356 
screening purposes.  357 
3.6.2 Suspect Screening  358 
The suspect screening database was applied to the pooled urine samples to demonstrate the applicability of 359 
these libraries. The aim of this work was to develop a reiterative tool to track the presence of the target 360 
compounds in wastewater by complementing the 51 target analytes with new targets identified via suspect 361 
screening The 51 compounds were selected as described above, however as shown in Table 2 not all were 362 
present or detected in the sewage-based samples. Suspect screening together with retrospective analysis allows 363 
the selection of new compounds, based on detection in the wastewater to be added to the quantitative target 364 
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method through the use of an authentic reference standard thereby facilitating decision-making and improving 365 
cost effectiveness. 366 
The continuum data for the three-music festival samples were peak detected using the processing settings 367 
described above. Following peak processing UNIFI provided a list of m/z values termed as candidates. The 368 
number of candidates for the samples were 11,220, 11,183 and 11,164 for each festival. The acceptance 369 
criterion for the tentative candidates is within the tolerance range described in the data processing section. 370 
Despite this, in this method the authors defined limit checks broader to perform the final step manually, 371 
meaning that after the evaluation of the candidates against the database UNIFI provided a new list with 182, 372 
151 and 131 tentative IDs respectively. Table S-7 shows some examples of positive identifications for the ID’s 373 
fulfilling the criteria consisted of a mass accuracy ±5 ppm, retention time ±0.5 min, isotope match ±5 ppm and 374 
a minimum of two detected ions in the HE. Sildenafil, a medicine to treat erectile dysfunction, zolpidem, 375 
prescription medication for the treatment of insomnia, and benzocaine and lidocaine, known cocaine cutting 376 
agents are interesting for future target analysis. In this case the 24 compounds identified (Table S-7) would 377 
move from the level 3 (tentative candidates) to the level 2 (probable structure) in the absence of the reference 378 
standards for the final confirmation [33]. 379 
In order to augment the suspect database used in this study, a non-target approach was used to net purchased 380 
NPS; 5/6-APB and N-adamantyl-1-pentylindole-3-carboxamide (commercial names: Benzo Fury and 2NE1-381 
APICA). Figures S-4 and S-5 illustrate the detection and identification of the 5/6-APB and N-adamantyl-1-382 
pentylindole-3-carboxamide. UNIFI automatically detects the sample components, and subsequently through 383 
the accurate mass spectra allows the identification of the unknown candidates. In contrast with the 384 
characterization analysis of the classic drugs, the NPS chromatograms are relatively clean since they are 385 
purchased in almost pure form without any additive or “cutting agent” as is shown in Figure S-4 and S-5 where 386 
only two peaks are present as the most abundant. As an example, Figure S-5 shows a chromatogram with the 387 
assigned fragments (159.0798 and 131.0488) from the accurate mass ion 176.1065 at 5.2 min. 388 
A common fragment approach was used also used as a complementary tool for the identification and 389 
subsequently introduction of 14 synthetic cannabinoids into the suspect database. Figure S-6 shows the total 390 
ion chromatogram of the 14 synthetic cannabinoids described in the picture together with the chromatogram of 391 
the common fragment m/z 155.0492 belonging to 8 of the synthetic cannabinoids. 392 
 393 
 394 
 395 
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4. CONCLUSIONS  396 
A high confidence multi-residue method using auto-SPE-UHPLC-QTOF for the determination of 51 drugs, 397 
pharmaceuticals and metabolites was validated and applied to different sewage-base samples. Meanwhile, this 398 
analytical procedure is also intended to fulfill the analytical challenge of the detection and reliable 399 
identification of NPS appearing in the market through the application of a suspect screening approach 400 
augmented by a reiterative process intended to both update the target multi-residue method, and the suspect 401 
screening list.  402 
The selection of HLB as an extraction sorbent and C18 as the chromatography column provides a broad and 403 
generic methodology for the rapid identification of a larger number of compounds dealing with the compromise 404 
between elimination of interfering matrix components (using more selective extraction procedures) or the 405 
unification of all requested features in just one method. The method has a satisfactory linear dynamic range and 406 
the sensitivity. Even though many papers have shown the capability of the HRMS screening techniques just for 407 
qualitative purposes, the high selectivity, accurate mass and the information provided by the fragments as mass 408 
defect or the isotopic pattern, make this method in a very reliable tool also for the quantification of drugs and 409 
emergent substances in wastewater. 410 
The described reiterative and dynamic workflow has been designed in order to constantly update the screening 411 
levels based on experimental data (Figure 3 Target analysis can be supplemented by simultaneously screening 412 
through the suspect database in order to identify new compound of interest, all in one injection. If a suspect 413 
candidate is identified, this candidate can be later confirmed by purchasing the reference standard and this 414 
compound can then be incorporated into the target method. Despite not being used in this work, non-target 415 
screening is an additional avenue of the described workflow which can enhance the potential of the approach. 416 
The application of this method was finally tested with different real samples showing an extensive list of 417 
confirmed compounds in different sewage-based samples confirming the broad applicability of the developed 418 
method. Two NPS were also introduced into the suspect database together with another 14 synthetic 419 
cannabinoids as part of the strategy to expand the library for further identification purposes in the future. 420 
 421 
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Figures and Tables 568 
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Figure1 571 
Different sewage-based samples used in this study 572 
 573 
 574 
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Figure 2 578 
2D mass chromatogram of the low energy channel (6eV ESI+) of a 100 ng/mL standard mix solution with all 579 
the target compounds, UNIFI (Waters Corporation, Milford MA, USA) 580 
 581 
582 
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 583 
 584 
Figure 3. Illustrative workflow diagram for the three different approaches developed in this study. 585 
 586 
587 
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 588 
Table 1 589 
Target compounds organized by their retention times with the experimental parameters. 590 
Compound Internal Standard tR Precursor ion Product ion Linear range 
   [M + H]+ (m/z) (ng mL-1) 
Morphine Atenolol-d7 1.17 286.14376 201.0910 0,5-100 
Hydroxycotinine Atenolol-d7 1.17 193.09714 134.0595 0,5-400 
Atenolol Atenolol-d7 1.26 267.1703 190.0863 0,5-200 
Salbutamol Atenolol-d7 1.28 240.1594 145.0648 1-100 
p-Hydroxymethamphetamine Atenolol-d7 1.31 166.12263 135.0798 2-100 
Paracetamol Atenolol-d7 1.62 152.07059 110.0601 2-400 
Cathinone Methcathinone-d3 1.75 150.09133 132.0808 5-400 
Gabapentin Gabapentin-d10 1.8 172.13319 154.1227 5-200 
Pseudoephedrine  Methcathinone-d3 1.96 166.12263 133.0886 5-400 
Methcathinone (Ephedrone) Methcathinone-d3 1.98 164.10698 146.0971 1-400 
Methylone Methylone-d3 2.16 208.09681 160.0757 0,25-400 
6-MAM Methylone-d3 2.29 328.15432 165.0699 0,5-400 
Amphetamine Amphetamine-d5 2.41 136.11207 91.0543 5-400 
MDA MDA-d5 2.47 180.10189 163.0754 10-200 
PMA MDMA-d5 2.53 166.12263 91.0543 2-400 
Methamphetamine Methamphetamine-d5 2.72 150.12771 119.0856 2-200 
MDMA MDMA-d5 2.75 194.11754 163.0754 2-400 
Dehydronorketamine Norketamine-d4 2.89 222.06801 205.0415 1-400 
PMMA MDMA-d5 2.98 180.13828 121.0648 2-400 
Benzoylecgonine Benzoylecgonine-d3 3.07 290.13867 168.1020 0,25-400 
Mephedrone (4-MMC) Mephedrone-d3 3.19 178.12263 160.1127 2-400 
Norketamine Norketamine-d4 3.21 224.08366 125.0153 5-200 
Ketamine Ketamine-d4 3.45 238.09931 125.0153 0,5-400 
4-MEC Ketamine-d4 3.7 192.13828 174.1278 0,5-400 
Methoxetamine Metoprolol-d7 4.12 248.16449 121.0648 0,25-400 
Metoprolol Metoprolol-d7 4.19 268.1907 116.1070 0,25-400 
Methylphenidate Metoprolol-d7 4.32 234.14884 84.0808 0,25-400 
Cocaine Cocaine-d3 4.83 304.15432 182.1176 0,25-200 
Cocaethylene  Cocaine-d3 5.87 318.16997 196.1333 0,25-400 
Propranolol Fentanyl-d5 6.28 260.16449 116.1070 0,25-200 
Fentanyl Fentanyl-d5 6.63 337.22742 188.1434 0,25-400 
AH-7921 Fentanyl-d5 7.02 329.11818 284.0611 0,25-400 
Citalopram Buprenorphine-d4 7.07 325.17105 109.0449 0,25-200 
Midazolam Buprenorphine-d4 7.14 326.08547 291.1167 0,25-400 
Buprenorphine Buprenorphine-d4 7.38 468.31081 414.2633 0,25-400 
Carbamazepine Buprenorphine-d4 7.54 237.10223 194.0965 0,25-200 
EDDP Atomoxetine-d7 7.75 278.19031 234.1277 0,25-400 
Atomoxetine Atomoxetine-d7 7.81 256.16958 148.1103 1-200 
Nitrazepam Oxazepam-d5 8.16 282.08731 236.0945 1-400 
Oxazepam Oxazepam-d5 8.22 287.05817 241.0528 2-400 
Clonazepam Oxazepam-d5 8.5 316.04833 270.0555 1-400 
Lorazepam Oxazepam-d5 8.6 321.0192 275.0138 5-400 
Alprazolam Oxazepam-d5 8.83 309.09014 281.0715 0,25-200 
Methadone Methadone-d3 8.89 310.21652 265.1587 0,25-400 
Flunitrazepam Diazepam-d5 9.19 314.09353 268.1007 1-400 
Etizolam Diazepam-d5 9.53 343.07786 314.0391 0,25-200 
Phenazepam Diazepam-d5 10.1 348.97382 196.1706 2-400 
Diazepam Diazepam-d5 10.91 285.07891 193.0886 0,25-200 
Diclofenac Diazepam-d5 11.4 296.02395 215.0496 5-400 
THC-OH THC-OH-d3 11.83 331.22675 313.2162 5-400 
THC-COOH THC-COOH-d3 11.85 345.20602 299.2009 5-400 
      
 
 591 
 592 
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Table 2 593 
Loads (mg day-1 1000 inhabitants-1) of detected analytes in influent wastewater samples from the Oslo (mean 594 
± SD) and Trondheim (mean, n=1) WWTPs 595 
a founded it at least one of the daily samples (not presented in all) 596 
Friday Saturday Friday Saturday Friday Saturday
28.02.14 08.03.14 21.03.14 29.03.14 04.04.14 12.04.14
Morphine 48.2 ±12.3 41.8 ±13.4 47.5 ±9.2 6.1 7.2 8.7 5.5 13.3 12.3
Hydroxycotinine 3873.8 ±616.9 1919.1 ±204.9 2155.9 ±243.6 239.5 331.7 500.1 577.7 575.3 636.3
Atenolol 165.7 ±22.0 134.3 ±21.1 136.2 ±6.5 45.0 75.3 53.3 53.2 95.8 77.1
Paracetamol 6323.7 ±1026.7 6335.2 ±153.2 4210.4 ±468.2 485.6 1129.3 1703.1 1481.7 2355.3 2209.2
Methylone
a 11.8 - nd - nd - nd nd nd nd nd nd
6-MAM 25.2 ±10.5 6.0 ±10.4 2.8 ±2.4 8.0 16.1 25.3 23.7 32.6 39.2
Amphetamine 51.5 ±10.8 38.1 ±7.6 51.1 ±4.1 76.5 124.1 91.2 53.2 91.8 56.9
MDMA 75.5 ±65.5 25.7 ±22.3 26.8 ±23.8 nd nd nd nd nd nd
Methamphetamine <LOQ - 26.3 ±9.7 25.8 ±2.4 14.2 26.3 11.6 35.2 50.1 49.6
Benzoylecgonine 214.3 ±86.8 216.3 ±24.1 240.9 ±59.1 3.5 14.5 5.8 9.0 9.0 12.2
Ketamine
a nd - 5.3 ±9.1 nd - nd nd nd nd nd nd
Methoxetamine
a 0.8 ±1.3 nd - nd - nd nd nd nd nd nd
Metoprolol 836.2 ±87.5 859.1 ±183.9 857.3 ±64.0 123.0 125.6 141.8 146.3 280.1 250.2
Methylphenidate nd - nd - nd - 0.6 1.2 2.7 1.3 2.7 3.0
Cocaine 92.5 ±35.5 77.1 ±18.5 88.7 ±23.6 0.8 2.1 3.1 2.0 3.4 4.0
Cocaethylene 7.3 ±6.7 9.8 ±1.3 6.1 ±1.7 nd nd nd nd nd nd
Propranolol 3.5 ±0.7 14.8 ±1.5 0.8 ±0.1 4.3 13.9 20.8 13.0 22.7 26.7
Citalopram 44.0 ±9.1 49.3 ±7.7 44.8 ±0.9 32.2 43.9 14.5 12.3 27.5 17.4
Buprenorphine nd - nd - nd - 214.5 292.5 96.7 81.8 183.5 115.7
Carbamazepine 258.3 ±29.2 294.6 ±16.6 248.0 ±27.1 52.1 52.2 35.0 69.2 116.7 112.7
EDDP 48.5 ±9.2 36.3 ±3.5 18.6 ±1.9 10.3 11.6 7.2 7.1 13.9 8.6
Oxazepam 153.2 ±32.3 125.0 ±25.9 144.0 ±6.5 72.6 119.8 69.3 94.7 141.4 140.9
Alprazolam nd - nd - nd - 7.5 798.8 462.0 631.0 942.5 939.1
Methadone 13.4 ±2.3 16.8 ±4.1 14.5 ±2.3 1.1 2.1 3.7 1.8 3.2 3.7
Diclofenac
b nd - nd - nd - 40.7 81.5 133.0 42.3 146.2 153.6
Trondheim, Spring 2014Oslo, February 2014
Analyte 1st weekend 2nd weekend 3rd weekend
 597 
 598 
 599 
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 Experimental Section 
Reagents 
The illicit drugs, pharmaceuticals and their metabolites reference substances selected for target analysis 
were cocaine, cocaethylene, benzoylecgonine, amphetamine, methamphetamine, 3,4-methylene-
dioxymethamphetamine (MDA), 3,4-methylenedioxyethylamphetamine (MDMA or ecstasy),para-
hydroxymethamphetamine, para-methoxyamphetamine (PMA), para-methoxy-N-methylamphetamine 
(PMMA), ketamine, dehydronorketamine, norketamine, methoxetamine, pseudoephedrine, cathinone, 
methcathinone (ephedrone), methylone, 4´-methyl-N-ethylcathinone (4-MEC), mephedrone (4-
MMC),methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), morphine, 6-
monoacetylmorphine (6-MAM), fentanyl, buprenorphine, AH-7921, hydroxycotinine, atenolol, 
salbutamol, gabapentin, paracetamol, metoprolol, methylphenidate, propranolol, citalopram, atomoxetine, 
carbamazepine, midazolam, nitrazepam, clonazepam, lorazepam, oxazepam, alprazolam, flunitrazepam, 
etizolam, phenazepam, diazepam, diclofenac, etizolam, carbamazepine, ∆-9-tetrahydrocannabidiol (THC), 
11-hydroxy-∆-9-tetrahydrocannabidiol (OH-THC), 11-nor-9-carboxy-∆-9-tetrahydrocannabidiol (THC-
COOH), which were obtained from Nerliens Meszansky (Oslo, Norway) as solutions in methanol 
(MeOH) or acetonitrile (ACN) at concentrations of 1 mg mL-1. Standard solutions of each compound 
were made at 100 ng mL-1 in methanol and then diluted into a final mix solution to a concentration of 1 
ng mL-1  
Synthetic cannabinoids and their selected biomarkers, JWH-073, XLR-11, UR-144, AM-2201, JWH-018, 
MAM-2201, JWH-122, 5-3-1-Naphthoyl-1H-indol-1-yl-pentanoic acid (JWH-018 N-pentanoic acid), 1-5-
hydroxypentyl-1H-indol-3-ylnaphthalen-1-yl-methanone (JWH 018 N-5-hydroxypentyl), 4-3-1-naphthoyl-
1H-indol-1-yl-butanoic acid (JWH-073 N-butanoic acid), 1-4-hydroxybutyl-1H-indol-3- ylnaphthalen-1-yl-
methanone (JWH-073 N-4-hydroxybutyl), 1-5-hydroxypentyl-1H-indol-3-yl4-methylnaphthalen-1-yl-
methanone (JWH-122 N-5-hydroxypentyl), 1-5-fluoro-4-hydroxypentyl-1H-indol-3-ylnaphthalen-1-
ylmethanone (AM-2201 N-4-hydroxypentyl), 1-5-hydroxypentyl-1H-indol-3-yl4-methoxyphenyl-
methanone (RCS-4 N-5-hydroxypentyl) were obtained from Chiron (Trondheim, Norway) in solutions of 
1 mL at 50 µg mL-1 in MeOH or ACN. 
Benzo Fury, 1-benzofuran-6-ylpropan-2-amine (6-APB) or 1-benzofuran-5-ylpropane-2-amine (5-APB), 
and 2NE1/APICA, N-adamantyl-1-pentylindole-3-carboxamide were purchased through online website.  
Deuterated standards were purchased from Nerliens Meszansky as solutions of 100 ng mL-1 in MeOH or 
ACN and were used as surrogate isotope labelled internal standards (ILIS) for quantification: atenolol-d7, 
atomoxetine-d7, diclofenac-d4, gabapentin-d10, metoprolol-d7, pregabalin-d6, benzoylecgonine-d3, 
cocaine-d3, ketamine-d4, norketamine-d4, mephedrone-d3, methcathinone-d3 (ephedrone-d3), 
methylone-d3, pseudoephedrine-d3, buprenorphine-d4, diazepam-d5, oxazepam-d5, fentanyl-d5, 
methadone-d3, amphetamine-d5, MDA-d5, MDMA-d5, methamphetamine-d5, THC-OH-d3, THC-
COOH-d3. Final standard mix solution was made in methanol at 1 ng mL-1. Finally all the standard 
solutions were stored in amber glass bottles at -20 °C.  
The ultrapure water was obtained by purifying demineralized water in an Elga Maxima Ultrapure Water 
purification system (Elga, Lane End, UK). Ammonium formate (for mas spectroscopy, ≥99.0%), HPLC-
grade formic acid (eluent additive for LC-MS) and UHPLC-grade water, MeOH and ACN were acquired 
from Sigma-Aldrich, Fluka for HPLC (Oslo, Norway) 
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Sewage-based samples 
Influent samples were collected from two wastewater treatment plants (WWTWs); VEAS WWTW in Oslo 
and Ladehammeren and Høvringen WWTWs in Trondheim Norway. 
Nine influent wastewater composite samples were collected during three consecutive weekends from 
VEAS sewage treatment plant, Oslo Norway, in February 2014. An ISCO Avalanche Portable 
Refrigerated Sampler (Lincoln, NE, USA) was used to collect the composite samples (50 mL, time 
proportional) every 30 minutes for the duration of the sampling period. Maximum storage time for the 
daily composite samples was 3 days at 0.5ºC in polypropylene bottles. The composite samples were 
transported every Monday in cooler bags and stored at -20 ºC until analysis to minimize the degradation 
of the analytes. The catchment area of VEAS is comprised of 63% of the Oslo population, around 
600,000 inhabitants. The total length of the tunnel is 42.3 km and the mean residence time in the sewer 
system is 5 hours (VEAS annual report 13’). The mean influent flow rate for each weekend was 600,820, 
775,327, and 410,970 m3/day, which is higher that the annual mean (273,196 m3 day-1 in 2013) and was 
due to increased precipitation during the sampling campaign. 
Six influent 24-hour composite wastewater samples were collected during February, March and April of 
2014 in two different sewage treatment plant located in Trondheim (Norway). Ladehammeren and 
Høvringen WWTPs treat the sewage from the city with an estimated population of 180,000 inhabitants. 
Samples were received frozen and analysed upon reception in the laboratory. Mean influent flow rates are 
described in the results section. 
The robustness of this work was also examined with the analysis of different sewage-based samples. The 
“Pharmaceuticals” version of the POCIS was made up of Oasis HLB sandwiched between 
polyethersulphone membranes as described in literature1. POCIS were deployed in the sedimentation 
overflow channel at VEAS, the Oslo WWTP, for two weeks. The study and collection of the pooled urine 
samples was conducted in Norway during the course of three different music festivals. Portable toilets 
were available to be used by the festival participants anonymously and no data on the number of users was 
collected. 
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Extraction procedure 
The HLB extraction disks were conditioned by washing and rinsing with methanol (10 mL) and water (10 
mL). Samples were automatically loaded and filtered (Fast Flow Pre-Filters, Horizon Technology) onto 
the disks at a flow rate of 100 mL min-1, and then the disks were washed 4 times with 5% methanol in 
water and dried under vacuum for 10 minutes. 
Then the samples were loaded directly onto the disk from the sample bottle and prior elution, the disk is 
air-dried under vacuum providing a shorter operational time. The analytes were finally eluted into a 
silanised glass vial with 2 cycles of 5% ammonium hydroxide in methanol and 2 cycles of 5% acetic acid in 
methanol. The total program time was approximately 25 minutes. In general this system is more simple, 
reproducible and cost-effective than the SPE cartridges. 
The final extracts were evaporated to around 100 µL under a gentle nitrogen stream at 35 ºC and 
reconstructed in 400 µL of 25% methanol aqueous solution. An aliquot was centrifuged and then 5 µL 
were injected into the UHPLC-QTOF. The general procedure is also described in the Table S-1.  
The “Pharmaceuticals” version of the POCIS were deployed in the wastewater treatment plant and 
subsequently the sorbent was removed and introduced in an empty SPE cartridge with Mili-Q water, 
washed twice with 6 mL of 5 % methanol in water and finally eluted with 6 mL of 0.5% ammonium 
hydroxide in methanol and 6 mL of 0.5% acetic in methanol. The eluent was evaporated under a stream 
of nitrogen and diluted to 1.5 mL with 13% methanol in water. 100 ng of the ILIS mix was added during 
the washing step.  
The pooled urine samples were firstly homogenized and then centrifuged during 20 minutes at 2500 rpm. 
5 mL of the supernatant was collected, spiked with 100 ng of the ILIS mix and introduced into the HLB 
cartridge. Washed with 2x6 mL 5 % methanol in water, the elution was finally done with 6 mL of 0.5% 
ammonium hydroxide in methanol and 6 mL of 0.5% acetic in methanol. The eluent was evaporated 
under a stream of nitrogen and diluted to 1 mL with 13% methanol in water. 
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Figure S-1 
Influence of silanisation on the recovery (%) of the studied compounds during the evaporation in the SPE extract vials. Recovery of 100 mL of MiliQ water spiked with 100 ng of the 
standard mix solution using HLB cartridges (n=3) 
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Figure S-2 
Recovery of the studied compounds after the evaporation to dryness at 50 °C of a 5 mL methanol solution with 100 ng of the mix standard solution (n=3) 
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Figure S-3 
Effect of the loading volume on the matrix effect. Matrix suppression average for 25 ILIS spiked into the extracts of 3 
different wastewater samples. The loading volumes were 100, 200, 300, and 400 mL and the final extract was 
reconstituted volume of 400 µL 
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Figure S-1 
Detection and identification of N-adamantyl-1-pentylindole-3-carboxamide in a sample purchased on internet under 
the name of “2NE1/APICA”. Extracted ion chromatogram of the 2NE1/APICA powder sample and the spectra in low 
and high energy time-of-flight. Possible fragment structures assigned manually by UNIFI 
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Figure S-2 
Detection and identification of 6-(2-aminopropyl)benzofuran (6-APB)/ 5-APB (5-(2-aminopropyl)benzofuran (5-APB) 
in a sample purchased on internet under the name of “Benzo Fury”. Extracted ion chromatogram of the Benzo Fury 
tablet sample and the spectra in low and high energy time-of-flight. Possible fragment structures assigned manually by 
UNIFI 
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Figure S-6 
Total ion chromatogram for the 14 synthetic cannabinoids of a standard mix at 250 ng/mL with the description of the 
main metabolites A). Common fragment (155.0492) chromatogram from four synthetic cannabinoids and their four 
metabolites B) 
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Table S-1 
SPE-DEX procedure 
Step Solvent Soak time Dry time 
Preconditioning Methanol (2 times) 20 s 10 s 
 
Water 20 s 10 s 
 
Water 20 s 0 s 
Sample loading - - - 
Washing 5% methanol/water(4 times) 10 s 30 s 
Disk drying - - 10 min 
Eluting 5% ammonium hydroxide in methanol 30 s 30 s 
 
5% ammonium hydroxide in methanol 30 s 2 min 
 
5% acetic acid in methanol 30 s 30 s 
 
5% acetic acid in methanol 30 s 2 min 
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Table S- 2 
Experimental parameters used for the validation and quantification of the target compounds: chromatographic retention times, exact mass of the protonated target compounds, 
validated linear range, correlation coefficient, mass error and the results of the instrumental performance 
      Accuracy (%) Precision (RSD%) 
Compound tR Precursor ion Linear range Linearity R2 Mass Errora Intra-day Inter-day Intra-day Inter-day 
  [M + H]+ (ng mL-1)  (mDa/ppm) Low High Low High Low High Low High 
              
Morphine 1.17 286.14376 0,5-100 0.995 -0.08/-0.29 94 101 94 101 1 1 3 2 
Hydroxycotinine 1.17 193.09714 0,5-400 0.999 0.09/046 92 97 88 98 3 2 5 5 
Atenolol 1.26 267.1703 0,5-200 1.000 -0.05/-0.2 108 99 108 99 3 0 3 0 
Salbutamol 1.28 240.1594 1-100 0.995 -0.17/-0.67 108 100 107 99 2 1 5 2 
p-Hydroxymethamphetamine 1.31 166.12263 2-100 0.998 -0.17/-0.99 96 102 99 101 7 2 7 2 
Paracetamol 1.62 152.07059 2-400 0.998 0/-0.02 98 101 104 101 3 2 9 5 
Cathinone 1.75 150.09133 5-400 0.991 -0.08/-0.52 93 104 92 104 3 2 3 1 
Gabapentin 1.8 172.13319 5-200 0.995 -0.04/-0.26 110 102 108 99 3 1 2 6 
Pseudoephedrine  1.96 166.12263 5-400 0.998 -0.31/-2.07 96 99 94 99 9 1 8 4 
Methcathinone (Ephedrone) 1.98 164.10698 1-400 0.998 -0.35/-2.49 93 100 96 100 1 0 3 0 
Methylone 2.16 208.09681 0,25-400 0.999 0.03/0.12 110 100 109 100 4 0 3 0 
6-MAM 2.29 328.15432 0,5-400 0.998 -0.01/-0.05 95 102 98 101 3 1 4 0 
Amphetamine 2.41 136.11207 5-400 0.993 -0.15/-1.31 88 104 98 104 5 1 12 1 
MDA 2.47 180.10189 10-200 0.994 0.04/0.29 109 104 108 103 6 4 6 4 
PMA 2.53 166.12263 2-400 0.999 -0.42/-2.59 110 100 107 100 2 1 5 1 
Methamphetamine 2.72 150.12771 2-200 0.999 -0.16/-1.10 105 101 104 100 4 1 5 1 
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MDMA 2.75 194.11754 2-400 0.999 -0.03/-0.16 100 100 100 100 4 1 3 1 
Dehydronorketamine 2.89 222.06801 1-400 0.998 0.22/0.98 106 99 108 97 7 0 7 2 
PMMA 2.98 180.13828 2-400 1.000 -0.42/-2.59 101 100 100 100 3 0 3 1 
Benzoylecgonine 3.07 290.13867 0,25-400 0.999 0.01/0.07 94 101 95 101 2 0 1 0 
Mephedrone (4-MMC) 3.19 178.12263 2-400 0.999 -0.14/-0.86 107 99 105 99 8 0 8 0 
Norketamine 3.21 224.08366 5-200 0.999 0.12/0.58 109 102 104 101 4 1 7 6 
Ketamine 3.45 238.09931 0,5-400 1.000 -0.35/-2.49 98 99 97 99 3 1 4 1 
4-MEC 3.7 192.13828 0,5-400 1.000 -0.09/-0.48 97 99 98 99 2 1 2 1 
Methoxetamine 4.12 248.16449 0,25-400 1.000 -0.06/-0.21 105 99 105 99 7 0 5 0 
Metoprolol 4.19 268.1907 0,25-400 0.999 -0.16/-0.61 102 100 101 100 1 1 2 1 
Methylphenidate 4.32 234.14884 0,25-400 1.000 0/-0.05 98 100 94 100 3 1 5 1 
Cocaine 4.83 304.15432 0,25-200 1.000 0/0.03 97 101 97 101 2 0 1 0 
Cocaethylene  5.87 318.16997 0,25-400 1.000 0.04/-0.13 96 102 96 101 1 1 1 1 
Propranolol 6.28 260.16449 0,25-200 0.998 -0.04/-0.13 105 99 105 94 2 1 2 6 
Fentanyl 6.63 337.22742 0,25-400 1.000 -0.24/-0.69 107 99 105 99 4 0 5 1 
AH-7921 7.02 329.11818 0,25-400 1.000 -0.1/-0.33 110 99 113 100 4 0 5 2 
Citalopram 7.07 325.17105 0,25-200 0.997 -0.14/-0.42 100 100 100 100 4 1 3 1 
Midazolam 7.14 326.08547 0,25-400 0.999 -0.03/-0.1 106 99 108 97 7 0 7 2 
Buprenorphine 7.38 468.31081 0,25-400 1.000 0.11/0.25 101 100 100 100 3 0 3 1 
Carbamazepine 7.54 237.10223 0,25-200 1.000 0.19/0.75 94 101 95 101 2 0 1 0 
EDDP 7.75 278.19031 0,25-400 0.999 -0.1/-0.33 107 99 105 99 8 0 8 0 
Atomoxetine 7.81 256.16958 1-200 0.999 -0.02/-0.07 109 102 104 101 4 1 7 6 
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Nitrazepam 8.16 282.08731 1-400 0.998 -0.09/-0.33 98 99 97 99 3 1 4 1 
Oxazepam 8.22 287.05817 2-400 0.997 -0.51/-1.78 97 99 98 99 2 1 2 1 
Clonazepam 8.5 316.04833 1-400 0.998 -0.35/-1.09 105 99 105 99 7 0 5 0 
Lorazepam 8.6 321.0192 5-400 0.994 -0.22/-0.69 102 100 101 100 1 1 2 1 
Alprazolam 8.83 309.09014 0,25-200 0.996 -0.04/-0.15 98 100 94 100 3 1 5 1 
Methadone 8.89 310.21652 0,25-400 0.999 0.39/1.24 97 101 97 101 2 0 1 0 
Flunitrazepam 9.19 314.09353 1-400 1.000 -0.07/-0.18 96 102 96 101 1 1 1 1 
Etizolam 9.53 343.07786 0,25-200 1.000 -0.08/-0.26 105 99 105 94 2 1 2 6 
Phenazepam 10.1 348.97382 2-400 0.998 -0.28/-0.82 107 99 105 99 4 0 5 1 
Diazepam 10.91 285.07891 0,25-200 1.000 0.05/0.19 110 99 113 100 4 0 5 2 
Diclofenac 11.4 296.02395 5-400 0.997 -0.02/-0.08 100 100 100 100 4 1 3 1 
THC-OH 11.83 331.22675 5-400 0.995 -0.17/-0.56 106 99 108 97 7 0 7 2 
THC-COOH 11.85 345.20602 5-400 0.992 0.17/0.5 101 100 100 100 3 0 3 1 
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Table S-3 
Method validation in influent wastewater (n=6) 
 
 
Compound 
 
 
Internal Standard 
 
 
Matrix 
Suppression 
Recovery  
 
Instrumental LOQ   
(ng mL-1) 
 
 
Theoretical LOQ    
(ng L-1) 
  
 
Information 
 
100 ng L-1 CV(%) 600 
ng L-
1 
CV(%)  
           
Morphine Atenolol-d7 38 73 9 68 10 0.40 4.2   
Hydroxycotinine Atenolol-d7 38 120 19 88 17 0.57 5.9 * high concentrations in "blank" 
Atenolol Atenolol-d7 38 92 2 91 12 0.35 3.7   
Salbutamol Atenolol-d7 38 88 7 90 8 0.81 8.5   
p-Hydroxymethamphetamine Atenolol-d7 38 - - - - 1.34 14.0 * high matrix suppression 
Paracetamol Atenolol-d7 38 - - - - 1.28 13.4 * high concentration in "blank" 
Cathinone Methcathinone-d3 34 ~LOQ ~LOQ 51 2 5.69 67.5   
Gabapentin Gabapentin-d10 30 - - - - 3.79 51.2 * high matrix suppression 
Pseudoephedrine  Methcathinone-d3 34 101 5 118 5 3.10 36.7   
Methcathinone (Ephedrone) Methcathinone-d3 34 85 7 94 1 0.85 10.0   
Methylone Methylone-d3 37 77 2 98 3 0.04 0.4   
6-MAM Methylone-d3 37 72 5 81 4 0.30 3.2   
Amphetamine Amphetamine-d5 14 77 9 90 13 3.06 85.6   
MDA MDA-d5 26 - - - - 11.95 187.0 * high matrix suppression 
PMA MDMA-d5 26 57 5 77 8 1.03 16.1   
MDMA MDMA-d5 26 69 4 69 3 1.53 24.0   
Methamphetamine Methamphetamine-d5 11 77 10 83 5 1.51 54.1   
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Dehydronorketamine Norketamine-d4 33 48 2 54 4 0.65 8.0   
PMMA MDMA-d5 26 74 8 79 2 0.90 14.0   
Benzoylecgonine Benzoylecgonine-d3 51 102 9 107 7 0.12 0.9   
Mephedrone (4-MMC) Mephedrone-d3 18 61 2 74 6 1.16 26.3   
Norketamine Norketamine-d4 33 76 5 76 11 2.89 35.5   
Ketamine Ketamine-d4 41 80 4 100 6 0.26 2.5   
4-MEC Ketamine-d4 41 73 4 91 5 0.28 2.7   
Methoxetamine Metoprolol-d7 40 32 7 41 3 0.19 1.9   
Metoprolol Metoprolol-d7 40 84 12 95 6 0.11 1.1   
Methylphenidate Metoprolol-d7 40 47 9 51 9 0.15 1.5   
Cocaine Cocaine-d3 52 93 11 103 7 0.07 0.6   
Cocaethylene  Cocaine-d3 52 90 9 101 6 0.11 0.9   
Propranolol Fentanyl-d5 33 102 18 119 11 0.06 0.8   
AH-7921 Fentanyl-d5 33 97 5 108 12 0.20 2.4   
Citalopram Buprenorphine-d4 24 72 14 84 10 0.09 1.5   
Fentanyl Fentanyl-d5 33 90 14 112 3 0.14 1.7   
Midazolam Buprenorphine-d4 24 98 3 119 6 0.09 1.5   
Buprenorphine Buprenorphine-d4 24 86 7 115 4 0.15 2.5   
Carbamazepine Buprenorphine-d4 24 118 6 130 6 0.14 2.3   
EDDP Atomoxetine-d7 23 77 16 103 11 0.11 2.0   
Atomoxetine Atomoxetine-d7 23 71 1 62 10 0.62 10.8   
Nitrazepam Oxazepam-d5 78 76 3 93 5 0.74 3.8   
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Clonazepam Oxazepam-d5 78 57 1 46 1 1.14 5.9   
Oxazepam Oxazepam-d5 78 113 15 104 14 2.23 11.5   
Lorazepam Oxazepam-d5 78 86 3 87 2 2.31 11.9   
Alprazolam Oxazepam-d5 78 75 15 100 14 0.16 0.8   
Methadone Methadone-d3 41 97 8 96 5 0.04 0.4   
Flunitrazepam Diazepam-d5 19 73 7 100 15 0.71 15.2   
Etizolam Diazepam-d5 19 66 13 84 10 0.09 2.0   
Phenazepam Diazepam-d5 19 104 9 118 9 1.50 32.2   
Diazepam Diazepam-d5 19 125 7 110 14 0.10 2.2   
Diclofenac Diazepam-d5 19 - - - - 2.94 62.9 * high matrix suppression 
THC-OH THC-OH-d3 19 - - - - 2.41 50.3 * high matrix suppression 
THC-COOH THC-COOH-d3 17 - - - - 3.22 76.7 * high matrix suppression 
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Table S-4 
Stability of the spiked analytes (1000 ng L-1) in influent WW (n=3) at pH 7. Difference (%)/ ± SD  
 Peak Area Difference (%)± SD 
Compound 5 h 8 h 120 h 
    
Morphine -24 ±20 -5 ±17 83 ±12 
Hydroxycotinine 22 ±5 82 ±1 54 ±4 
Atenolol -9 ±5 -10 ±4 -20 ±2 
Salbutamol 9 ±10 1 ±9 -3 ±8 
p-Hydroxymethamphetamine 7 ±14 -1 ±9 70 ±22 
Paracetamol -1 ±14 -8 ±8 -88 ±8 
Gabapentin -9 ±25 -28 ±8 -32 ±11 
Pseudoephedrine  9 ±10 13 ±15 0 ±11 
Methcathinone (Ephedrone) -4 ±18 -8 ±22 -33 ±11 
Methylone 6 ±62 -27 ±21 -53 ±12 
6-MAM -14 ±7 -16 ±8 -21 ±7 
Amphetamine 14 ±3 23 ±6 33 ±7 
MDA 15 ±11 -2 ±18 -96 ±18 
PMA 3 ±20 16 ±7 10 ±7 
MDMA 29 ±36 6 ±6 12 ±6 
Methamphetamine -10 ±8 -15 ±33 23 ±29 
Dehydronorketamine -11 ±11 -7 ±20 -13 ±18 
PMMA -4 ±33 17 ±9 6 ±10 
Benzoylecgonine 19 ±8 30 ±7 56 ±8 
Mephedrone (4-MMC) -1 ±1 3 ±1 7 ±1 
Norketamine -12 ±6 -24 ±17 -25 ±20 
Ketamine 4 ±27 -13 ±8 -25 ±5 
4-MEC 5 ±16 -2 ±18 -32 ±12 
Methoxetamine -4 ±4 -6 ±10 13 ±0 
Metoprolol -6 ±3 -9 ±3 -5 ±3 
Methylphenidate -10 ±11 -32 ±4 -88 ±11 
Cocaine -9 ±6 -23 ±8 -75 ±3 
Cocaethylene  -1 ±5 -6 ±5 -42 ±4 
Propranolol 8 ±6 6 ±5 -27 ±6 
AH-7921 18 ±15 9 ±5 -26 ±11 
Citalopram 13 ±9 14 ±6 -23 ±7 
Fentanyl 9 ±13 10 ±2 -25 ±0 
Midazolam -3 ±7 5 ±10 -54 ±8 
Buprenorphine 18 ±12 23 ±10 -41 ±14 
Carbamazepine 4 ±6 4 ±6 -11 ±5 
EDDP 45 ±4 82 ±5 77 ±6 
Atomoxetine 20 ±4 22 ±1 -60 ±7 
Nitrazepam -14 ±12 -8 ±9 -79 ±9 
Clonazepam -2 ±11 -3 ±10 -65 ±9 
Oxazepam -7 ±8 -1 ±8 -36 ±8 
Lorazepam -1 ±10 -3 ±7 -46 ±11 
Alprazolam -1 ±6 3 ±7 -23 ±8 
Methadone 3 ±6 7 ±8 -41 ±7 
Flunitrazepam 0 ±5 0 ±7 -64 ±4 
Etizolam -1 ±5 2 ±10 -41 ±7 
Phenazepam 2 ±8 3 ±15 -70 ±9 
Diazepam -5 ±7 -8 ±10 -59 ±7 
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Table S-5 
Concentration values (ng/POCIS) for the most commonly detected drugs in the passive samplers 
Analyte Date of collection and concentration values (ng/POCIS) 
 
29.08.2013 16.09.2013 30.09.2013 15.10.2013 29.10.2013 15.11.2013 02.12.2013 18.18.2013 03.01.2014 21.01.2014 
Morphine 34.9 39.1 48.2 22.3 22.9 18.6 25.1 22.1 16.2 30.8 
Hydroxycotinine 18.7 14.6 17.1 44.7 28.4 40.9 24.5 36.9 27.8 31.7 
Atenolol 68.0 68.4 89.5 36.4 44.9 45.7 69.8 44.0 26.3 58.3 
Paracetamol 718.6 521.1 940.7 778.3 779.2 699.9 1086.3 1091.3 360.5 1055.9 
MDMA 33.1 33.9 48.4 25.3 25.5 4.8 49.4 32.9 20.8 26.9 
Benzoylecgonine 78.0 77.8 85.6 43.1 52.7 46.1 86.0 58.9 39.4 58.9 
Methoxetamine 3.3 3.5 3.8 1.5 1.9 2.0 2.6 1.4 1.2 1.8 
Metoprolol 448.5 518.4 738.6 384.7 358.3 408.5 541.5 436.6 194.7 370.0 
Cocaine 106.1 110.4 133.9 69.5 68.2 72.9 121.8 85.4 38.3 68.8 
Propranolol 38.3 54.5 31.2 32.5 31.5 42.9 41.5 40.2 14.3 24.6 
Citalopram 93.8 119.1 87.6 72.7 70.2 118.0 132.8 103.7 27.2 74.0 
Carbamazepine 244.3 399.5 440.1 226.0 226.3 205.8 267.1 220.0 98.8 177.6 
EDDP 97.1 169.4 139.4 103.9 81.9 91.9 114.9 78.7 20.4 74.5 
Methadone 15.1 17.2 18.9 15.8 13.1 15.2 16.9 15.1 7.0 11.3 
Oxazepam 696.9 927.5 744.8 692.4 525.6 675.3 754.7 745.0 187.1 421.1 
Diclofenac 134.2 144.8 109.9 92.2 149.7 103.5 133.9 125.3 47.4 102.8 
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Table S-6 
Concentration (ng/L) values of target compounds in pooled urine samples (5 mL) from anonymous Norwegian music 
festivals 
Compound Festival 1 Festival 2 Festival 3 
Atenolol - 900 - 
Morphine - - 440 
Paracetamol* 3.6 42.2 1320.2 
Gabapentin - 5960 - 
Amphetamine 5840 - 20900 
Methamphetamine 1360 820 1780 
MDMA* - - 60.6 
MDA - - 4340 
Cocaine - 480 520 
Benzoylecgonine 1340 78820 14680 
Cocaethylene -   
Citalopram - - 2360 
Propranolol 540 - 720 
Carbamazepine 3520 7860 - 
Oxazepam 340 1100 - 
Methylphenidate - -  
Methadone 240 - - 
THC-COOH 1020  7080 
*(µg/L) 
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Table S-7. Occurrence of the identified suspect candidates in the pooled urine samples by UHPLC-QTOF using the 
suspect database.  
Compound Number of Identified LE Ions Retention Time Elemental Composition m/z 
1-Benzylpiperazine (BZP) 2 1.23 C11H16N2 176.13134 
Hydroxy-metoprolol 3 1.43 C15H25NO4 283.17834 
Caffeine 3 2.08 C8H10N4O2 194.08036 
Nadolol 3 2.27 C17H27NO4 309.19399 
Metoclopramide 4 3.02 C14H22ClN3O2 299.14004 
Lidocaine 2 3.19 C14H22N2O 234.1732 
O-demethyl-venlafaxine 3 3.2 C16H25NO2 263.18851 
Remifentanil 3 4.37 C20H28N2O5 376.1998 
Disopramide 3 4.56 C21H29N3O 339.23104 
Zolpidem 4 5.19 C19H21N3O 307.16845 
Venlafaxine 3 5.29 C17H27NO2 277.20416 
Acetildenafil 5 5.37 C25H34N6O3 466.26922 
Enalapril 2 5.49 C20H28N2O5 376.1998 
Mepyramine 2 5.52 C17H23N3O 285.1841 
Sildenafil 2 6.19 C22H30N6O4S 474.2049 
Benzocaine 2 6.5 C9H11NO2 165.07897 
Imipramine 2 7.67 C19H24N2 280.19393 
Cetirizine 2 8.28 C21H25ClN2O3 388.15535 
Trimipramine 2 8.44 C20H26N2 294.20958 
Irbesartan 2 9.08 C25H28N6O 428.23244 
Irbesartan 2 9.28 C25H28N6O 428.23244 
Cinnarizine 2 10.48 C26H28N2 368.22523 
Fluocinonide 2 11.17 C26H32F2O7 494.21159 
Orlistat 4 13.24 C29H53NO5 495.39234 
 
 
(1) Harman, C.; Reid, M.; Thomas, K. V. Environ Sci Technol 2011, 45, 5676-5682. 
 
